Bellicum’s BPX-501 Gets Orphan Drug Status

Bellicum Pharmaceuticals’ T-cell therapy BPX-501 has reeled in orphan drug status for the treatment of immunodeficiency and graft versus host disease following allogeneic hematopoietic stem cell transplant.

The designation covers BPX-501 in combination with activator agent rimiducid. It currently is being evaluated in Phase 1/2 clinical studies in leukemia, lymphoma and genetic blood diseases.